Evidence map›Paper›PMID 16883312›Full record

Trial reportBone marrow transplantation2006

Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.

X-J Huang, D-H Liu, K-Y Liu, L-P Xu, H Chen, W Han, Y-H Chen, J-Z Wang, Z-Y Gao, Y-C Zhang and 3 more

Erratum issued 2 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 175 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
175citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01037764 phase2terminatednot on this mapstarted 2010, after this paper: background citation

Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia in Remission Using HLA-matched Sibling Donors, HLA-matched Unrelated Donors, or HLA-mismatched Familial Donors-A Phase 2 Study

TypeinterventionalSponsorAsan Medical CenterRan2010 to 2016Enrolled100ConditionsAcute Lymphoid LeukemiaArmsalloHCT
NCT02428517 terminatednot on this mapstarted 2015, after this paper: background citation

A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission

TypeobservationalSponsorAsan Medical CenterRan2015 to 2016Enrolled20ConditionsPrecursor Cell Lymphoblastic Leukemia-LymphomaArmsAlloHCT for Young/MSD, AlloHCT for Young/MUD&FMD, AlloHCT for Old/MSD, AlloHCT for Old/MUD&FMD
3 · Its place in the literature

Who cites it

175 citing papers in PubMed, 1 synthesis or guideline pooled it, 430 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. G-CSF-primed haplo-identical HSCT with intensive immunosuppressive and myelosuppressive treatments does not increase the risk of pre-engraftment bloodstream infection: a multicenter case-control study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

115 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Dosage error in article text
5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

X-J HuangPeking University Institute of Hematology, People's Hospital, Beijing, PRC. xjhrm@medmail.com.cn
D-H Liu
K-Y Liu
L-P Xu
H Chen
W Han
Y-H Chen
J-Z Wang
Z-Y Gao
Y-C Zhang
Q Jiang
H-X Shi
D-P Lu
Peking University People's Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many patients who require allogeneic hematopoietic stem cell transplantation (allo-HSCT) lack a human leukocyte antigen (HLA)-matched donor. Here, we report a protocol for haploidentical allo-HSCT that combines granulocyte-colony stimulating factor primed bone marrow (G-BM) and peripheral blood stem cells (PBSC) without in vitro T-cell depletion (TCD). In this study, 171 patients, including 86 in high-risk group, underwent transplantation from haploidentical family donors. All patients achieved sustained, full donor chimerism. One hundred and eleven patients were alive in remission at a median of 682 (253-1502) days. The cumulative incidence of grade III-IV acute graft-versus-host disease (GVHD) was 23% and that of extensive chronic GVHD, 47%; these were not influenced by HLA disparity. Patients younger than 15 years had less grade III-IV acute GVHD than older patients (P=0.044). The 2-year probability of relapse was 12% for standard-risk disease and 39% for high-risk disease. The 2-year probability of leukemia-free survival (LFS) was 68% for standard-risk patients and 42% for high-risk patients (P=0.0009). Grade III-IV acute GVHD was associated with better LFS (P=0.0017). The results require confirmation and show that G-BM combined with PBSC from haploidentical family donors, without in vitro TCD, may be used as a good source of stem cells for allo-HSCT.

Indexed as

HaplotypesAdolescentAdultBlood DonorsChildChild, PreschoolFemaleGraft vs Host DiseaseGranulocyte Colony-Stimulating FactorHematologic NeoplasmsHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansMaleMiddle AgedTime FactorsGranulocyte Colony-Stimulating Factor

Identifiers

PMID16883312
OpenAlexW2079110478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.